Veracyte stock rises 10.77 percent toward its yearly high
Published on 09/25/2026 at 09:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Veracyte stock rose 10.77 percent to USD 48.54 on Nasdaq on September 24, 2026, leaving the shares 20.31 percent below their 52-week high of USD 60.91. The move follows a quarter with USD 150.3 million in revenue and a USD 180 million urology diagnostics acquisition announced on September 14, 2026. The central investor question is whether faster testing growth can support the company valuation.
Q2 revenue reaches USD 150.3 million
Veracyte generated USD 150.3 million in total revenue in Q2 2026, an increase of 15 percent from the prior-year quarter, according to Yahoo Finance. Testing revenue reached USD 145.7 million, up 19 percent year over year, while total testing volume increased 14 percent to 48,389 tests.
The earnings mix also showed operating leverage. GAAP net income was USD 25.5 million in Q2 2026, while adjusted EBITDA reached USD 44 million, equal to 29.2 percent of revenue, according to the same earnings-call transcript.
Bladder diagnostics expand the pipeline
On September 14, 2026, MarketScreener reported that Veracyte agreed to acquire Convergent Genomics for USD 180 million. The transaction includes USD 150 million in upfront cash and up to USD 30 million in milestone payments tied to UroAmp reimbursement efforts.
Management also raised full-year 2026 revenue guidance to USD 590 million-596 million from a prior range of USD 582 million-592 million, according to Yahoo Finance. The new range implies 14 percent to 15 percent growth and gives revenue execution a larger role in the stock valuation.
UBS lifts target to USD 65
On September 9, 2026, MarketScreener reported that UBS raised its Veracyte price target from USD 52 to USD 65 while maintaining its Buy rating. The target is USD 16.46 above the September 24 price, a 33.92 percent premium, making the gap between operating progress and market valuation especially visible.
Stock remains below its yearly high
Veracyte stock was trading at USD 48.54 on Nasdaq on September 24, 2026, with a daily gain of 10.77 percent. The price remained 20.31 percent below the 52-week high of USD 60.91, while market capitalization stood at USD 3,873,132,804.
Veracyte market snapshot
- Company: Veracyte, Inc.
- Ticker: VCYT
- Trading venue: NASDAQ
- Price (as of September 24, 2026, 4:00 p.m. ET): USD 48.54
- Market capitalization: USD 3,873,132,804 (as of September 24, 2026)
- 52-week range: USD 29.45-60.91 (as of September 24, 2026)
- Sector / Industry: Healthcare / Diagnostics and Research
